Annovis Bio Files Provisional Patent for New Buntanetap Manufacturing Process

Annovis Bio

MALVERN, PAAnnovis Bio Inc. (NYSE: ANVS) has filed a provisional patent covering the manufacturing process of novel solid forms of buntanetap. This move aims to strengthen the company’s control over the production of its promising neurodegenerative disorder treatment.

The patent details methods for creating a new crystalline form of buntanetap, which has shown remarkable stability and efficacy. It includes the entire synthesis process, ensuring a product that is over 99.9% pure and suitable for large-scale manufacturing. Key benefits of this new process include high yields, avoidance of harmful reagents, and a purer end product.

This development is critical for Annovis as it advances its drug pipeline. The new crystal form’s Chemistry, Manufacturing, and Controls (CMC) protocol was submitted to the FDA and will be discussed in July. The goal is to continue developing buntanetap and file a New Drug Application (NDA) with this improved form.

Michael Christie, Ph.D., Vice President of Process Chemistry at Annovis, emphasized the importance of this patent. “Securing our manufacturing rights for new forms of buntanetap ensures we maintain control over the production process, protect our intellectual property, and continue our mission to deliver novel therapeutics for patients suffering from neurodegenerative disorders,” he said.

This patent filing represents a significant step for Annovis Bio, reinforcing its commitment to innovation and patient care in the neurodegenerative disease space.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.